Kiniksa Pharma Files 2025 Proxy Statement

TL;DR

Kiniksa proxy filed, annual meeting June 3rd. Vote your shares!

AI Summary

Kiniksa Pharmaceuticals International, plc filed its definitive proxy statement (DEF 14A) on April 21, 2025, for its annual meeting on June 3, 2025. The filing concerns the company's governance and shareholder matters, with no specific financial transactions or executive compensation details immediately apparent from this initial review.

Why It Matters

This filing provides shareholders with crucial information regarding upcoming votes on company leadership and governance, allowing them to make informed decisions at the annual meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting, not indicating any immediate financial distress or significant operational changes.

Key Players & Entities

• Kiniksa Pharmaceuticals International, plc (company) — Registrant
• 20250421 (date) — Filing Date
• 20250603 (date) — Meeting Date

FAQ

From the Filing

0001104659-25-036852.txt : 20250421 0001104659-25-036852.hdr.sgml : 20250421 20250421163038 ACCESSION NUMBER: 0001104659-25-036852 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20250603 FILED AS OF DATE: 20250421 DATE AS OF CHANGE: 20250421 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 25853714 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 DEF 14A 1 tm252382-4_def14a.htm DEF 14A tm252382-3_nonfiling - none - 36.6664953s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒    Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ​ ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ​ ☒ Definitive Proxy Statement ​ ☐ Definitive Additional Materials ​ ☐ Soliciting Material Under §240.14a-12 ​ KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC ​ (Name of Registrant as Specified in its Charter)     ​ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) ​ Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ​ ☐ Fee paid previously with preliminary materials. ​ ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. ​   TABLE OF CONTENTS TABLE OF CONTENTS April 21, 2025 Dear Shareholder: You are cordially invited to attend the 2025 Annual Meeting of Shareholders (the “ Annual Meeting ”) of Kiniksa Pharmaceuticals International, plc, to be held on June 3, 2025, at 3:00 p.m. British Summer Time (10:00 a.m. Eastern Daylight Time) at Third Floor, 23 Old Bond Street, London, United Kingdom W1S 4PZ. The Notice of Annual Meeting and proxy statement on the following pages describe the matters to be presented at the Annual Meeting. Please see the heading “ Who Can Attend the Annual Meeting? ” in the proxy statement for more information about how to attend the Annual Meeting in person. Whether or not you plan to attend the Annual Meeting, it is important that your shares be represented and voted at the Annual Meeting. I urge you to promptly vote and submit your proxy by phone, the Internet, or, if you received paper copies of our proxy materials and proxy card, by signing, dating and mailing the proxy card in the return envelope provided therewith. If you have received our Notice of Internet Availability of Proxy Materials, the instructions regarding how you can vote are in such notice. If you have received a proxy card, then instructions regarding how you can vote are on the proxy card. If you decide to attend the Annual Meeting, you will be able to vote in person, even if you have previously submitted your proxy. Thank you for your support. Sincerely, Sanj K. Patel Chief Executive Officer and Chairman of the Board   TABLE OF CONTENTS ​       Notice of Annual Meeting of Shareholders To be held June 3, 2025 ​ KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC THIRD FLOOR 23 OLD BOND STREET LONDON, UNITED KINGDOM W1S 4PZ ​ This year’s Annua